COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities

Stopped The Principal Investigators and CureVac decided to terminate the trial early following a change to the risk/benefit profile.

Conditions

• Coronavirus
• Covid19
• SARS-CoV-2
• Severe Acute Respiratory Syndrome

Interventions

• BIOLOGICAL: CVnCoV Vaccine

Sponsor

CureVac